Asherman's syndrome medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m Robot: Automated text replacement (-mgibson@perfuse.org +charlesmichaelgibson@gmail.com & -kfeeney@perfuse.org +kfeeney@elon.edu) |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Asherman's syndrome}} | {{Asherman's syndrome}} | ||
'''Editor(s)-in-Chief:''' [[C. Michael Gibson]], M.S.,M.D. [mailto: | '''Editor(s)-in-Chief:''' [[C. Michael Gibson]], M.S.,M.D. [mailto:charlesmichaelgibson@gmail.com] Phone:617-632-7753; [[User:Csinfor|Canan S Fornusek, Ph.D.]]; '''Associate Editor-In-Chief:''' {{MUT}} | ||
==Overview== | ==Overview== | ||
==Medical Therapy== | ==Medical Therapy== |
Revision as of 13:41, 1 November 2012
Asherman's syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Asherman's syndrome medical therapy On the Web |
American Roentgen Ray Society Images of Asherman's syndrome medical therapy |
Risk calculators and risk factors for Asherman's syndrome medical therapy |
Editor(s)-in-Chief: C. Michael Gibson, M.S.,M.D. [1] Phone:617-632-7753; Canan S Fornusek, Ph.D.; Associate Editor-In-Chief: M.Umer Tariq [2]
Overview
Medical Therapy
Hormonal therapy with synthetic or conjugated estrogen is usually prescribed following surgery to stimulate endometrial growth thereby preventing the walls of the uterus from re-adhering.
More studies are needed to evaluate which method of treatment is most likely to have a successful outcome.